Travere Therapeutics, Inc.
TVTXNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $4.93B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $22.59$68.73
- Volume (live)
- -
- Avg. volume (3M)
- 1.80M
Travere Therapeutics (TVTX) Stock Price & Financial Analysis
Travere Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $49.46 - $52.56 |
|---|---|
| 52-Week High | $68.73 |
| 52-Week Low | $22.59 |
| Open | $52.56 |
| Volume (last close) | 1.83M |
| Average Volume (3M) | 1.80M |
| Revenue (TTM) | 591.33M |
|---|---|
| Net Income (TTM) | -43.46M |
| Free Cash Flow (TTM) | 30.45M |
| EPS (TTM) | −$0.46 |
| Profit Margin | -7.35% |
| Operating Margin | -6.84% |
| Return on Equity (ROE) | -177.24% |
| Debt to Equity | 24.83 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 4.93B |
|---|---|
| Shares Outstanding | 93.48M |
| Price to Sales (P/S) | 8.35 |
| Price to Book (P/B) | 201.24 |
| EV/EBITDA | 1651.75 |
| 50-Day MA | $61.83 |
|---|---|
| 200-Day MA | $45.69 |
| 1-Year Change | +93.23% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Travere Therapeutics at a Glance
As of the Oct 16, 2026 close, Travere Therapeutics (TVTX) has a market capitalization of $4.93B. The stock trades at 8.3× sales. Over the trailing twelve months it lost $43.46M on revenue of $591.33M and generated $30.45M of free cash flow. Revenue grew 77.1% year over year.
As of its latest reported balance sheet, it holds $117.73M in cash and securities against $608.94M of debt, a net debt position of $491.21M.
Travere Therapeutics does not currently pay a dividend.
The share price is up 93.2% over the past year. At $49.60 (the Oct 16, 2026 close) it sits within its 52-week range of $22.59 to $68.73, above its 200-day moving average of $45.69.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $72.63, 46.4% above the Oct 16, 2026 close.
Frequently Asked Questions About Travere Therapeutics
What is the current stock price for TVTX?
As of the Oct 16, 2026 close, TVTX stock trades at $49.60. The 52-week range is $22.59–$68.73, with a day range of $49.46–$52.56.
What is the P/E ratio for TVTX?
The P/E ratio (Price-to-Earnings) for TVTX is shown in the Key Statistics section. This valuation metric helps compare Travere Therapeutics, Inc. to industry peers.
Does TVTX pay dividends?
Travere Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for TVTX?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for TVTX is Buy. The average 12-month price target is $72.63, a 46.4% upside from the Oct 16, 2026 close of $49.60.
What is the market cap of TVTX?
As of the Oct 16, 2026 close, Travere Therapeutics's market capitalization is $4.64B, classifying it as a mid-cap company. Travere Therapeutics operates in the Healthcare sector within the Biotechnology industry.